NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management...
Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the...
NEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has recently...
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today...
Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused...
– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m,...
– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on...
Barchart Research What to Expect from ARVN Earnings ARVN Generated May 6, 2026 Current Price $10.26 EPS Estimate $$-0.95 Consensus Rating Moderate Buy Average Move 7.19% Arvinas: Wall Street Bracing for...
NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced...